Sugi Predict

Sugi Predict / Compounds / SCHEMBL159889

SCHEMBL159889

SCHEMBL159889

CC(C)COc1cc[c]cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.43
▸ HPGD P15428 3/20 0.43
▸ POLB P06746 3/20 0.43
▸ XBP1 P17861 1/20 0.43
▸ MAOA P21397 1/20 0.42
▸ PTGS1 P23219 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ LMNA P02545 3/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ ALOX12 P18054 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Magnesium Chloride Anhydrous SCHEMBL27511760 0.92 MAPT (0.39) MAPTHPGDPOLBXBP1MAOA
SCHEMBL27531239 0.92 MAPT (0.39) MAPTHPGDPOLBXBP1MAOA
SCHEMBL123415 0.83 MAPT (0.55) MAPTHPGDPOLBXBP1MAOA
SCHEMBL17133871 0.83 PTGS1 (0.40) MAOAPTGS1CYP2C9CYP2C19LMNA
SCHEMBL6622827 0.83 LMNA (0.64) MAPTPOLBMAOAPTGS1KDM4E
SCHEMBL27982479 0.83 PTGS1 (0.40) MAOAPTGS1CYP2C9CYP2C19LMNA
SCHEMBL11555241 0.83 PTGS1 (0.40) MAPTHPGDPOLBXBP1MAOA
SCHEMBL27917023 0.83 LMNA (0.64) MAPTPOLBMAOAPTGS1KDM4E
SCHEMBL4776330 0.81 FFAR1 (0.46) MAPTMAOAPTGS1LMNA
SCHEMBL8072049 0.81 FFAR1 (0.46) MAPTMAOAPTGS1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114206886-B Gold (III) compound, method for preparing the same, and organic light emitting device using the same 广东聚华印刷显示技术有限公司 2024-02-27 — — CN claimed
CN-114206886-A Luminescent gold (III) compound, method for preparing same, and organic light emitting device using same 广东聚华印刷显示技术有限公司 2022-03-18 — — CN claimed
WO-2021016814-A1 LUMINESCENT GOLD (III) COMPOUND, METHOD FOR PREPARING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME GUANGDONG JUHUA PRINTED DISPLAY TECHNOLOGY CO., LTD. (CN) 2021-02-04 — — WO claimed
CN-106232120-B Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2- (1H) -ones 爱尔皮奥治疗有限公司 2021-01-08 — — CN claimed
US-10772874-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. 2020-09-15 — — US claimed
CN-110903262-A Oxadiazole substituted benzene sulfonamide compound, preparation method thereof and application of oxadiazole substituted benzene sulfonamide compound as carbonic anhydrase inhibitor 中国人民解放军军事科学院军事医学研究院 2020-03-24 — — CN claimed
US-10272072-B2 Compounds and compositions for the inhibition of NAMPT FORMA TM, LLC (US) 2019-04-30 — — US claimed
CN-106554325-B A kind of preparation method of chirality benzene sulfinyl aminated compounds 上海交通大学 2019-02-22 — — CN claimed
CN-108250087-A A kind of synthetic method of 4- isobutoxies benzylamine 常州大学 2018-07-06 — — CN claimed
US-20170368039-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT FORMA TM, LLC (US) 2017-12-28 — — US claimed
WO-2000077010-A2 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES DU PONT PHARMACEUTICALS COMPANY (US) 2000-12-21 — — WO claimed
WO-2000077002-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES DU PONT PHARMACEUTICALS COMPANY (US) 2000-12-21 — — WO claimed
US-5935976-A Antiviral ethers of aspartate protease substrate isosteres NOVARTIS CORPORATION (US) 1999-08-10 — — US claimed
US-5807891-A RETROVIRUSES NOVARTIS AG (CH) 1998-09-15 — — US claimed
CN-1132756-A Antiviral ethers of aspartate protease substrate isosteres CIBA GEIGY AG (CH) 1996-10-09 — — CN claimed
EP-0708085-A2 Antiviral ethers of aspartate protease substrate isosteres CIBA-GEIGY AG (CH) 1996-04-24 — — EP claimed
EP-0366329-B1 Halogeno-4-methylpyrazoles and process for preparing the same NISSAN CHEMICAL IND LTD (JP) 1996-03-20 — — EP claimed
WO-1995023603-A1 USE OF 2-AMINO-4,5,7,8-TETRAHYDRO-6H-THIAZOLO[5,4-D]AZEPINES SUBSTITUTED IN POSITION 6 AS MEDICAMENTS HAVING AN ANTI-DEPRESSANT EFFECT, AND PREPARATION THEREOF DR. KARL THOMAE GMBH (DE) 1995-09-08 — — WO claimed
EP-0366328-B1 PROCESS FOR PREPARING 4-METHYLPYRAZOLES NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1993-05-19 — — EP claimed
US-4604471-A PLASTIC STABILIZERS BASF AKTIENGESELLSCHAFT (DE) 1986-08-05 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170368039-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 MAPT 519/4885HPGD 321/4885POLB 2930/4885
US-10772874-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NQO1 MAPT 268/4885HPGD 173/4885POLB 1931/4885
US-10272072-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NQO1 MAPT 268/4885HPGD 173/4885POLB 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.